Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera ...

New research explores the complex relationship between female infertility and gynecological cancers, revealing minimal links ...

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk ...

Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...

As the Affordable Care Act passed its 15th anniversary this year, Supreme Court Justices continue to deliberate the fate of ...

John Michael O'Brien, PharmD, MPH, discussed the changes in managed care over the past 30 years to commemorate the 30th ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't ...

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...